Medicenna Therapeutics (OTCMKTS:MDNAF – Get Free Report) announced its quarterly earnings data on Thursday. The company reported $999.00 earnings per share (EPS) for the quarter, Zacks reports.
Medicenna Therapeutics Stock Up 2.2%
OTCMKTS:MDNAF opened at $0.29 on Friday. Medicenna Therapeutics has a 12 month low of $0.25 and a 12 month high of $1.43. The stock has a 50-day moving average price of $0.37. The stock has a market capitalization of $26.82 million, a P/E ratio of -2.64 and a beta of 1.71.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.
Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.
Featured Articles
- Five stocks we like better than Medicenna Therapeutics
- BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
